S&P Futures
3,594.75 -6.75 (-0.19%) Dow Futures
28,813.00 +12.00 (+0.04%) Nasdaq Futures
10,973.50 -62.00 (-0.56%) Russell 2000 Futures
1,670.50 +0.70 (+0.04%) Crude Oil
81.55 +2.06 (+2.59%) Gold
1,670.70 -1.30 (-0.08%)
Abbott Laboratories (ABT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 98.29 |
| Open | 98.71 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 900 |
| Day's Range | 96.67 - 99.50 |
| 52 Week Range | 96.67 - 142.60 |
| Volume | |
| Avg. Volume | 4,713,676 |
| Market Cap | 169.448B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 20.20 |
| EPS (TTM) | 4.79 |
| Earnings Date | Oct 18, 2022 - Oct 24, 2022 |
| Forward Dividend & Yield | 1.88 (1.94%) |
| Ex-Dividend Date | Oct 13, 2022 |
| 1y Target Est | 124.94 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
Related Research
- Abbott LaboratoriesWeekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.RatingFair ValueEconomic Moat2 months agoArgus Research
- Reuters
UPDATE 1-Bubs Australia seeks permanent market access from U.S. FDA
Baby formula maker Bubs Australia Ltd said on Monday it is seeking permanent access to the U.S. market after the Food and Drug Administration (FDA) spelled out how companies that have been filling a temporary shortage can become long-term suppliers. Bubs said it had lodged a letter of intent with the U.S. FDA for permanent market access to October 2025 and beyond, adding that the FDA will issue a letter of acknowledgement in response. Global infant formula manufacturers have been importing goods into the United States after the country's health regulator relaxed its import policy to address a nationwide shortage partly triggered by Abbott Laboratories' manufacturing plant in Michigan recalling some products in February.
- ACCESSWIRE
Our Steps Toward a More Diverse and Inclusive World
For more than 130 years, Abbott has been known as a company that helps people live healthier lives.
- The Wall Street Journal
Congress Votes to Suspend Tariffs on Baby Formula Ingredient to Boost Supply
Lawmakers said they expected the legislation would make formula easier to find, especially for families in the WIC supplemental-nutrition program.
